trial summary · NCT07619521
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial record from the TrialBase DB dataset, status RECRUITING, condition Advanced Pancreatic Ductal Adenocarcinoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with trastuzumab deruxtecan (DS-8201a) works for the treatment of pancreatic ductal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. DS-8201a is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Giving selumetinib with DS-8201a may be safe, tolerable and/or effective in treating patients with advanced, unresectable or metastatic pancreatic ductal adenocarcinoma.
Source record: https://clinicaltrials.gov/study/NCT07619521
Facts
| registry id | NCT07619521 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Advanced Pancreatic Ductal Adenocarcinoma |
| sponsor | National Cancer Institute (NCI) |
| sponsor class | NIH |
| enrollment | 31 |
| start date | 2027-06-01 |
| primary completion | 2028-09-08 |
| completion | 2028-09-08 |
| results posted | not reported |
Conditions
- Advanced Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
- Biospecimen Collection
- Diagnostic Imaging Testing
- Echocardiography Test
- Multigated Acquisition Scan
- Selumetinib
- Trastuzumab Deruxtecan
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.